CAS: 1287241-26-2

PAC-1-d8 is a monoclonal antibody that binds to the protein phosphatase 1 (PP1) and inhibits its activity. PAC-1-d8 is used in cancer research to study the effects of PP1 on tumor cells. It has been shown to inhibit tumor growth in breast cancer, melanoma, lymphoma, and solid tumors. PAC-1-d8 is administered intravenously or intraperitoneally and it has also been shown to have few side effects in mice with breast cancer.

Applications Labelled PAC-1 is a caspase 3 activator. Caspase activation is a key strategy in cancer therapy. Caspase 3 is a key executioner caspase and direct effector of apoptosis. Hallmark of many cancers is the circumvention of signal in the activation of executioner caspases and loss of apoptotic response. EC50 for caspase 3 activation = 0.33 μM and caspase 7= 4.5 μM. The IC50 for apoptosis induction = 0.92 μM. Elevated caspase 3 level in cancerous cell lines and tissues allows PAC-1 to selectively induce apoptosis in tissues. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Slee, E., et al.: J. Biol. Chem., 276, 7320 (2001), Pop, C., et al.: Biochemistry, 42, 12311 (2003), Li, L., et al.: Science, 305, 1471 (2004), Green, D., et al.: J. Clin. Invest., 115, 2610 (2005), Satoh, T., et al.: Clin. Cancer Res., 15, 3872 (2009),